ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1770

Subglottic Stenosis and Endobronchial Disease in Granulomatosis with Polyangiitis

Kaitlin Quinn1,2, Cailin Sibley3, Alexander Gelbard4, Arlene Sirajuddin5, Marcela A. Ferrada6, Marcus Chen7, David Cuthbertson8, Simon Carette9, Nader A. Khalidi10, Curry L. Koening11, Carol Langford12, Carol A. McAlear13, Paul A. Monach14, Larry W. Moreland15, Christian Pagnoux16, Philip Seo17, Ulrich Specks18, Antoine G. Sreih19, Steven R. Ytterberg20, Peter A. Merkel21 and Peter C. Grayson22, 1Georgetown University Hospital, Washington, DC, 2Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, 3Oregon Health & Science University, Portland, OR, 4Vanderbilt University Medical Center, Nashville, TN, 5National Institutes of Health, Bethesda, MD, 6Critical Care, National Institutes of Health, Bethesda, MD, 7NHLBI, National Institutes of Health, Bethesda, MD, 8Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, 9Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 10Rheumatology, McMaster University, Hamilton, ON, Canada, 11Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, 12Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 13Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 14Section of Rheumatology, Boston University School of Medicine, Boston, MA, 15Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, 16Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 17Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 18Mayo Clinic College of Medicine, Rochester, MN, 19Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 20Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, 21University of Pennsylvania, Philadelphia, PA, 22National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Wegener's granulomatosis and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Vasculitis – ANCA-Associated Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

 

Background/Purpose:

Damage to the large airways is a devastating complication of granulomatosis with polyangiitis (GPA).  Identification of patient subsets at particular risk for airway disease and development of non-invasive screening methods to detect tracheobronchial disease is an unmet need in GPA.  This study aimed to characterize patients with subglottic stenosis (SGS) and bronchial disease and test whether dynamic expiratory-phase CT is useful to detect airway damage in patients with GPA.

 

Methods: i) A retrospective analysis of a multi-center cohort of patients with GPA identified demographic and clinical features associated with the presence of SGS or endobronchial involvement; ii) A subset of patients with GPA underwent a dynamic chest CT at a single center, assessed by a central reader blinded to clinical status.  Differences were assessed by the chi square test and ANOVA with post-hoc Tukey test to account for multiple comparisons.

 

Results:

Data from 962 patients with GPA from 9 centers were used for the initial phase analyses.  As outlined in Table 1, SGS was identified in 95 (10%) patients with no differences in ANCA subtype in patients with SGS compared to the overall cohort.  Patients with SGS were more likely to be female (72% vs 53%, P < 0.01), younger at time of diagnosis (36 vs 49 years, p < 0.01), and less likely to have constitutional, cardiovascular, renal, or nervous system involvement.  Among 95 patients in the cohort with nasal septal perforation and saddle nose deformities, 28 (29%) and 27 (30%), respectively, also had SGS. 

Endobronchial disease was seen in 59 (6%) patients.  Compared to the full cohort, patients with endobronchial involvement were younger at time of diagnosis, more likely to have ENT involvement and be PR3-ANCA positive (78% vs 63%, p=0.02), but less likely to be ANCA-negative (0% vs 9%, p = 0.02) or have renal disease. There was no association between endobronchial involvement and sex. Patients with SGS were more likely to have endobronchial involvement.  Concomitant SGS and endobronchial involvement (25 patients) was not associated with sex (60% vs 55% female, p = 0.60).

Six of ten patients screened by dynamic chest CT had large-airway pathology.  Isolated SGS was confirmed by imaging in two female patients.  Previously unknown tracheobronchomalacia was discovered in 4 patients, including one male patient thought to have isolated SGS.

 

Conclusion:

Both SGS and endobronchial disease are moderately common in GPA and each manifestation is associated with various other aspects of GPA.  SGS is more commonly seen in female patients with GPA, whereas bronchial involvement is not associated with sex.  There should be a low threshold to evaluate airway disease in GPA, especially in younger patients, and those with destructive sinonasal disease.  Dynamic expiratory phase chest CT is a potential non-invasive screening test for tracheobronchial disease in GPA.

 

 

 

 

 

 

 

 

 

Table 1:    Clinical Features in Patients with Granulomatosis with Polyangiitis with Subglottic Stenosis and/or Endobronchial disease

 

 

SGS-Yes

N=95

SGS-No

N=867

P-value

Endobronchial-Yes

N=59

Endobronchial-No

N=886

P-value

 

Sex (Female, %)

68 (72%)

457 (53%)

<0.01

33 (56%)

485 (55%)

0.86

 

Age at diagnosis

(Years ± SD)

35.7 ± 15

48.7 ± 17

<0.01

39.8 ± 2.3

47.7 ± 0.6

<0.01

 

Age at symptom onset (Years ± SD)

33.8 ± 14

47.6 ± 17

<0.01

39.2 ± 2.3

46.5 ± 0.6

<0.01

 

Race (Caucasian,%)

90 (95%)

788 (92%)

0.31

55 (93%)

813 (92%)

0.69

 

Anti-PR3-ANCA

60 (63%)

549 (64%)

0.9

46 (78%)

557 (63%)

0.02

 

Anti-MPO-ANCA

20 (21%)

199 (23%)

0.6

8 (14%)

205 (23%)

0.09

 

ANCA-negative

81 (90%)

748 (92%)

0.5

0 (0%)

76 (9%)

0.02

 

CLINICAL FEATURES

 

Constitutional

66 (70%)

690 (81%)

0.02

47 (87%)

610 (80%)

0.21

 

Musculoskeletal

53 (56%)

544 (63%)

0.17

36 (61%)

556 (63%)

0.74

 

Cutaneous

23 (24%)

251 (29%)

0.32

16 (27%)

257 (29%)

0.73

 

Eye

29 (31%)

232 (27%)

0.49

14 (24%)

247 (28%)

0.47

 

ENT

95 (100%)

640 (75%)

<0.01

53 (98%)

582 (77%)

<0.01

 

SGS

N/A

N/A

N/A

25 (42%)

66 (8%)

<0.01

 

Nasal perforation

28 (29%)

67 (11%)

<0.01

10 (18%)

84 (13%)

0.24

 

Saddle nose deformity

27 (30%)

62 (10%)

<0.01

12 (21%)

78 (12%)

0.04

 

Cardiovascular

0 (0%)

35 (4%)

0.04

1 (2%)

23 (3%)

0.39

 

Gastrointestinal

2 (2%)

27 (3%)

0.57

1 (2%)

28 (3%)

0.52

 

Pulmonary

69 (72%)

574 (67%)

0.29

59 (100%)

577 (66%)

<0.01

 

Endobronchial

25 (38%)

34 (6%)

<0.01

N/A

N/A

N/A

 

Renal

37 (39%)

540 (63%)

<0.01

22 (42%)

495 (65%)

<0.01

 

Nervous system

12 (13%)

202 (24%)

0.02

12 (23%)

197 (23%)

0.76

 

SGS=subglottic stenosis, Endobronchial=endobronchial disease, SD=standard deviation,
ANCA=anti-neutrophil cytoplasmic antibody,PR3=proteinase 3, MPO=myeloperoxidase

 

 


Disclosure: K. Quinn, None; C. Sibley, None; A. Gelbard, None; A. Sirajuddin, None; M. A. Ferrada, None; M. Chen, None; D. Cuthbertson, None; S. Carette, None; N. A. Khalidi, None; C. L. Koening, None; C. Langford, Bristol-Myers Squibb, 2,GlaxoSmithKline, 2,ChemoCentryx, 2,Genentech, Inc., 2,Bristol-Myers Squibb, 9,AbbVie Inc., 9; C. A. McAlear, None; P. A. Monach, None; L. W. Moreland, None; C. Pagnoux, None; P. Seo, None; U. Specks, None; A. G. Sreih, None; S. R. Ytterberg, None; P. A. Merkel, None; P. C. Grayson, None.

To cite this abstract in AMA style:

Quinn K, Sibley C, Gelbard A, Sirajuddin A, Ferrada MA, Chen M, Cuthbertson D, Carette S, Khalidi NA, Koening CL, Langford C, McAlear CA, Monach PA, Moreland LW, Pagnoux C, Seo P, Specks U, Sreih AG, Ytterberg SR, Merkel PA, Grayson PC. Subglottic Stenosis and Endobronchial Disease in Granulomatosis with Polyangiitis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/subglottic-stenosis-and-endobronchial-disease-in-granulomatosis-with-polyangiitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subglottic-stenosis-and-endobronchial-disease-in-granulomatosis-with-polyangiitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology